CardiolRx™ harnesses the properties of cannabidiol to inhibit the inflammasome pathway

CardiolRx™ harnesses the properties of cannabidiol to inhibit the inflammasome pathway, a critical intracellular process that contributes to inflammation and fibrosis. By targeting this pathway, Cardiol aims to reduce the detrimental effects of inflammation in heart disease, which can lead to conditions like chronic heart failure, resulting in hospitalization, physical limitations, and diminished quality of life for affected patients. The company has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to evaluate CardiolRx™ in clinical trials for recurrent pericarditis and acute myocarditis. These two con- ditions are important contributors to heart failure and other life threatening complications. The MAVERIC Program, designed to assess CardiolRx™’s effectiveness in treating recurrent pericarditis, includes the ongoing MAVERIC-Pilot study (Phase II), the MAVERIC-2 trial (Phase II/III), and the upcoming MAVER- IC-3 trial (Phase III). This program aims to demonstrate the drug’s potential to reduce the inflammation and pain caused by recurrent pericarditis, a disease characterized by chest pain, fatigue, and hospitalizations.